Differences in local immune cell landscape between Q fever and atherosclerotic abdominal aortic aneurysms identified by multiplex immunohistochemistry

  1. Kimberley RG Cortenbach
  2. Alexander HJ Staal
  3. Teske Schoffelen
  4. Mark AJ Gorris
  5. Lieke L Van der Woude
  6. Anne FM Jansen
  7. Paul Poyck
  8. Robert Jan Van Suylen
  9. Peter C Wever
  10. Chantal P Bleeker-Rovers
  11. Mangala Srinivas
  12. Konnie M Hebeda
  13. Marcel van Deuren
  14. Jos W Van der Meer
  15. Jolanda M De Vries
  16. Roland RJ Van Kimmenade  Is a corresponding author
  1. Radboud Institute for Molecular Life Sciences, Netherlands
  2. Radboud University Medical Centre, Netherlands
  3. Jeroen Bosch Ziekenhuis, Netherlands
  4. Radboud University Medical Center, Netherlands

Abstract

Background: Chronic Q fever is a zoonosis caused by the bacterium Coxiella burnetii which can manifest as infection of an abdominal aortic aneurysm (AAA). Antibiotic therapy often fails, resulting in severe morbidity and high mortality. Whereas previous studies have focused on inflammatory processes in blood, the aim of this study was to investigate local inflammation in aortic tissue.

Methods: Multiplex immunohistochemistry was used to investigate local inflammation in Q fever AAAs compared to atherosclerotic AAAs in aorta tissue specimen. Two six-plex panels were used to study both the innate and adaptive immune system.

Results: Q fever AAAs and atherosclerotic AAAs contained similar numbers of CD68+ macrophages and CD3+ T cells. However, in Q fever AAAs the number of CD68+CD206+ M2 macrophages was increased, while expression of GM-CSF was decreased compared to atherosclerotic AAAs. Furthermore, Q fever AAAs showed an increase in both the number of CD8+ cytotoxic T cells and CD3+CD8-FoxP3+ regulatory T cells. Lastly, Q fever AAAs did not contain any well-defined granulomas.

Conclusions: These findings demonstrate that despite the presence of pro-i is associated with an immune suppressed micro environment.

Funding: This work was supported by SCAN consortium: European Research Area - CardioVascualar Diseases (ERA-CVD) grant [JTC2017-044] and TTW-NWO open technology grant [STW-14716].

Data availability

All data generated or analyzed during this study are included in the manuscript and uploaded to Dryad (http://dx.doi.org/10.5061/dryad.bzkh189b4).Figure 3 - Source data 3; Figure 5 - Source data 5; Figure 6 - Source figure 6; Figure 7 - Source figure 7 contain numerical data used to generate the figures.

The following data sets were generated
    1. Cortenbach KR
    (2021) Vascular Q fever inflammation
    Dryad Digital Repository, doi:10.5061/dryad.bzkh189b4.

Article and author information

Author details

  1. Kimberley RG Cortenbach

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2717-5527
  2. Alexander HJ Staal

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  3. Teske Schoffelen

    Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  4. Mark AJ Gorris

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  5. Lieke L Van der Woude

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  6. Anne FM Jansen

    Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  7. Paul Poyck

    Department of Surgery, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  8. Robert Jan Van Suylen

    Department of Pathology, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Netherlands
    Competing interests
    No competing interests declared.
  9. Peter C Wever

    Department of Medical Microbiology and Infection Control, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, Netherlands
    Competing interests
    No competing interests declared.
  10. Chantal P Bleeker-Rovers

    Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  11. Mangala Srinivas

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  12. Konnie M Hebeda

    Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4181-3302
  13. Marcel van Deuren

    Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  14. Jos W Van der Meer

    Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands
    Competing interests
    Jos W Van der Meer, Senior editor, eLife.
  15. Jolanda M De Vries

    Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
    Competing interests
    No competing interests declared.
  16. Roland RJ Van Kimmenade

    Department of Pathology, Radboud University Medical Centre, Nijmegen, Netherlands
    For correspondence
    Roland.vanKimmenade@radboudumc.nl
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8207-8906

Funding

European Research Area - Cardiovascular Diseases (JTC2017-044)

  • Kimberley RG Cortenbach

TTW-NWO Open Technology (STW-14716)

  • Alexander HJ Staal

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The medical ethics committees of the institutions approved the study, in line with the principlesoutlined in the Declaration of Helsinki (Radboudumc: 2017-3196; Jeroen Bosch Hospital:2019.05.02.01).

Copyright

© 2022, Cortenbach et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 586
    views
  • 94
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kimberley RG Cortenbach
  2. Alexander HJ Staal
  3. Teske Schoffelen
  4. Mark AJ Gorris
  5. Lieke L Van der Woude
  6. Anne FM Jansen
  7. Paul Poyck
  8. Robert Jan Van Suylen
  9. Peter C Wever
  10. Chantal P Bleeker-Rovers
  11. Mangala Srinivas
  12. Konnie M Hebeda
  13. Marcel van Deuren
  14. Jos W Van der Meer
  15. Jolanda M De Vries
  16. Roland RJ Van Kimmenade
(2022)
Differences in local immune cell landscape between Q fever and atherosclerotic abdominal aortic aneurysms identified by multiplex immunohistochemistry
eLife 11:e72486.
https://doi.org/10.7554/eLife.72486

Share this article

https://doi.org/10.7554/eLife.72486

Further reading

    1. Medicine
    Mitsuru Sugimoto, Tadayuki Takagi ... Hiromasa Ohira
    Research Article

    Background:

    Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP.

    Methods:

    This multicenter study enrolled 2074 patients who underwent ERCP. Among them, 1037 patients each were randomly assigned to the development and validation cohorts. In the development cohort, the risk score model for predicting PEP was established via logistic regression analysis. In the validation cohort, the performance of the model was assessed.

    Results:

    In the development cohort, five PEP risk factors that could be identified before ERCP were extracted and assigned weights according to their respective regression coefficients: –2 points for pancreatic calcification, 1 point for female sex, and 2 points for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the pancreatic duct procedures (treated as ‘planned pancreatic duct procedures’ for calculating the score before ERCP). The PEP occurrence rate was 0% among low-risk patients (≤0 points), 5.5% among moderate-risk patients (1–3 points), and 20.2% among high-risk patients (4–7 points). In the validation cohort, the C statistic of the risk score model was 0.71 (95% CI 0.64–0.78), which was considered acceptable. The PEP risk classification (low, moderate, and high) was a significant predictive factor for PEP that was independent of intraprocedural PEP risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8–6.3; p<0.01).

    Conclusions:

    The PEP risk score allows an estimation of the risk of PEP prior to ERCP, regardless of whether the patient has undergone pancreatic duct procedures. This simple risk model, consisting of only five items, may aid in predicting and explaining the risk of PEP before ERCP and in preventing PEP by allowing selection of the appropriate expert endoscopist and useful PEP prophylaxes.

    Funding:

    No external funding was received for this work.

    1. Medicine
    Yao Li, Hui Xin ... Wei Zhang
    Research Article

    Estrogen significantly impacts women’s health, and postmenopausal hypertension is a common issue characterized by blood pressure fluctuations. Current control strategies for this condition are limited in efficacy, necessitating further research into the underlying mechanisms. Although metabolomics has been applied to study various diseases, its use in understanding postmenopausal hypertension is scarce. Therefore, an ovariectomized rat model was used to simulate postmenopausal conditions. Estrogen levels, blood pressure, and aortic tissue metabolomics were analyzed. Animal models were divided into Sham, OVX, and OVX +E groups. Serum estrogen levels, blood pressure measurements, and aortic tissue metabolomics analyses were performed using radioimmunoassay, UHPLC-Q-TOF, and bioinformatics techniques. Based on the above research content, we successfully established a correlation between low estrogen levels and postmenopausal hypertension in rats. Notable differences in blood pressure parameters and aortic tissue metabolites were observed across the experimental groups. Specifically, metabolites that were differentially expressed, particularly L-alpha-aminobutyric acid (L-AABA), showed potential as a biomarker for postmenopausal hypertension, potentially exerting a protective function through macrophage activation and vascular remodeling. Enrichment analysis revealed alterations in sugar metabolism pathways, such as the Warburg effect and glycolysis, indicating their involvement in postmenopausal hypertension. Overall, this current research provides insights into the metabolic changes associated with postmenopausal hypertension, highlighting the role of L-AABA and sugar metabolism reprogramming in aortic tissue. The findings suggest a potential link between low estrogen levels, macrophage function, and vascular remodeling in the pathogenesis of postmenopausal hypertension. Further investigations are needed to validate these findings and explore their clinical implications for postmenopausal women.